InvestorsHub Logo
Followers 276
Posts 35950
Boards Moderated 2
Alias Born 04/05/2012

Re: sorkin post# 2668

Saturday, 04/22/2017 3:20:50 AM

Saturday, April 22, 2017 3:20:50 AM

Post# of 7747
CYTR ~> today announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators' choice in patients with relapsed and refractory soft tissue sarcomas (STS) has been selected for an oral presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago.

D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.